Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - 2 hrs 31 mins ago
Cramer's watching earnings next week as he seeks stocks worth buying, not selling, in this market.
Final Glance: Biotechnology companies
AP - Fri Aug 08, 5:06PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Midday Glance: Biotechnology companies
AP - Fri Aug 08, 12:51PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri Aug 08, 9:51AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Celgene Shares Up 15.6% Since SmarTrend's Buy Recommendation (CELG)
Comtex SmarTrend(R) - Fri Aug 08, 9:51AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 3 months, Celgene has returned 15.64% as of today's recent price of $85.50.
Mylan Misses Q2 Earnings and Sales Estimates, Adjusts View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 10:15AM CDT
Mylan's (MYL) second quarter earnings fell short of the Zacks Consensus Estimate by a penny.
Health Canada Approves ABRAXANE® Plus Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Cancer
CNW Group - Wed Aug 06, 7:00AM CDT
High unmet need addressed with first new approved treatment in eighteen years
ClearBridge Value: Making It A Top Mutual Fund Again
at Investor's Business Daily - Tue Aug 05, 5:30PM CDT
How do you follow a legend? That's been one of the challenges for Sam Peters, who has been lead manager of $2.7 billion ClearBridge Value since taking the baton from Bill Miller about two years ago. Miller -- who still runs $2.1 billion Legg Mason...
Amgen's Multiple Myeloma Drug Kyprolis Succeeds - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 5:21PM CDT
Amgen (AMGN) intends to submit regulatory applications based on this study in the first half of 2015.
Celgene Falls 1.02% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 05, 4:34PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $85.97 to a high of $87.70. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $86.20 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Celgene to Potentially Rebound after Yesterday's 1.02% Sell Off
Comtex SmarTrend(R) - Tue Aug 05, 4:34PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $85.97 to a high of $87.70. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $86.20 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Regeneron Misses on Earnings in Q2, Eylea Drives Sales Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 2:02PM CDT
Regeneron (REGN) recorded higher than expected revenues due to strong Eylea sales.
Critical Alerts For Advanced Micro Devices, Celgene, Weibo, SunPower, and Time Warner Released By InvestorsObserver
PR Newswire - Tue Aug 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMD, CELG, WB, SPWR, and TWX.
'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.